Change Password!
Reset Password!
A multi-center, observational, real-world cohort study was conducted to explore the safety and effectiveness of vedolizumab in biologically naive individuals with Crohn’s disease and ulcerative colitis.
Among elderly patients with IBD (inflammatory bowel disease),
vedolizumab (humanized monoclonal antibody) was found to be safe and effective
as a first-line biological. It displayed high rates of clinical response and
steroid-free remission at both induction and maintenance.
A
multi-center, observational, real-world cohort study was conducted to explore
the safety and effectiveness of vedolizumab in biologically naive individuals
with Crohn’s disease and ulcerative colitis.
From the cohort of the Sicilian Network for Inflammatory Bowel Disease (SN-IBD), the web-based data of consecutive biologically naive patients with Crohn’s disease and ulcerative colitis treated with vedolizumab from July 2016 to December 2019 were extracted.
The study recruited a total of 172 consecutive patients (Crohn’s disease: N=88; Ulcerative colitis: N=84; median age 66.0 years). Participants were followed for a median follow-up of 58.8 weeks.
After 14 and 52 weeks, the percentage of patients reporting clinical response and achieving steroid-free remission is illustrated in the following table and figure:
CRP: C-reactive protein; CS: Clinical steroid
Vedolizumab
may be used as a first-line biological, particularly among elderly IBD patients
as it is safe and effective.
United European Gastroenterology Journal
Effectiveness and safety of vedolizumab in biologically naïve patients: A real-world multi-centre study
Fabio Salvatore Macaluso et al.
Comments (0)